The objective of this study was to determine the effects of androgen depletion by 5a-reductase inhibitor (eg epristeride), pure antiandrogen (eg casodex) or C17-20 lyase inhibitor (eg YM116) on rat prostate carcinogenesis induced by administration of 3,2 0 -dimethyl-4-aminobiphenyl (DMAB). DMAB was subcutaneously administered on male F344 rats for the ®rst 20 weeks. Epristeride (10 and 50 mg/kg, three times per week), casodex (15 and 30 mg/kg, three times per week) or YM116 (15 and 30 mg/kg, three times per week) were administered orally for 40 consecutive weeks. Then, all accessory sex organs were studied for the formation of neoplastic lesions by histological examination.
Introduction
Prevention of prostate cancer carcinogenesis by 5a-reductase inhibitor (eg ®nasteride) 1 ± 3 and pure antiandrogen (eg casodex) 4, 5 has been veri®ed at the developing stage from microscopic cancer to macroscopic cancer in rats in our previous studies. 6, 7 However, in a rat prostate carcinogenetic model induced by 3,2 0 -dimethyl-4-aminobiphenyl (DMAB) and high-dose exogenous testosterone, which was established by Shirai et al 8, 9 and used in our previous studies, 6, 7 androgen-dependency both in carcinogenesis and the development process has not been proved and a similarity with clinical prostate cancer has not been established. On the other hand, rat prostate cancer developed in the ventral lobe that is induced by DMAB alone has been proven to have androgen receptors and to be androgen-dependent 10 ± 12 in its growth. Using this carcinogenetic model we have studied the effect of 5a-reductase inhibitor (epristeride), pure antiandrogen (casodex) and C17-20 lyase inhibitor (YM116) on the induction of prostate cancer. YM116 is known to suppress androgen production both in the adrenal gland and in the testis. 13 Figure 1 presents the experimental design of this study. One-hundred and seventy-two F344 male rats aged 6 weeks (purchased from Charles River Japan Inc., Kanagawa, Japan) were allocated to seven groups. Animal care was in accordance with guidelines put forth by the Yamanouchi Research Laboratory. DMAB (Nard Co.
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Ltd., Osaka, Japan) at a dose of 50 mg/kg body weight was injected subcutaneously to all animals 10 times at two-week intervals in accordance with the method described by Shirai et al. 4 Group 1 (control, n 28) was administered only DMAB. Five-alpha-reductase inhibitor (epristeride; Ono Pharm. Co., Ltd, Japan), pure-antiandrogen (casodex; Zeneca Co. Ltd), and C17-20 lyase inhibitor (YM116; Yamanouchi Pharm. Co. Ltd) were administered orally by gavage for 40 consecutive weeks for the following experimental groups, through to the end of the experimental period: groups 2 (n 24) and 3 (n 24) were administered epristeride in dosages of 10 and 50 mg/kg, respectively, three times per week; groups 4 (n 24) and 5 (n 24) were administered casodex in dosages of 15 and 30 mg/kg, respectively, three times per week; and groups 6 (n 24) and 7 (n 24) were administered YM116 in dosages of 15 and 30 mg/kg, respectively, three times per week. The doses of the drugs administered in this study were decided based on our previous studies. 6, 7 All rats surviving at the end of the 60-week experimental period were autopsied, and the principal organs were macroscopically inspected. Serum samples were taken at the autopsy and the concentrations of testosterone and luteinizing hormone (LH) were measured. Animals that died after 50 weeks during the study period were also autopsied, and the presence or absence of prostate carcinoma was determined. These animals were included in the effective number in this study. The accessory sex organs were excised and ®xed in 10% neutral buffered formalin. These were then separated into the ventral lobe, dorsolateral lobe and anterior lobe of the prostate gland and the seminal vesicle, and their weights were recorded. The ventral lobe of the prostate was prepared as two sections: the dorsolateral lobe was prepared as one coronal section including the urethra; Figure 1 DMAB (Nard Co. Ltd., Osaka, Japan) at a dose of 50 mg/kg body weight was injected subcutaneously once every 2 weeks, to a total of 10 doses. F344 rats (6 weeks old) were divided into seven groups (24 animals/group). The rats in group 1 were administered only DMAB. In addition, the rats in groups 2 and 3 were administered epristeride (Ono Pharma Co. Ltd., Tokyo, Japan) by oral gavage at 10 and 50 mg/kg, respectively, three times a week beginning with the 21st week of the experiment until the completion of the study. By use of the same route and schedule, the rats in groups 4 and 5 were administered casodex (Zeneca Co. Ltd., Osaka, Japan) at 15 and 30 mg/kg, respectively, and the rats in groups 4 and 5 were administered YM116 (Yamanouchi Pharma Co. Ltd., Tokyo, Japan) at 15 and 30 mg/kg, respectively.
Effects of antiandrogenic agents
H Akaza et al and the specimens of the anterior lobe and the seminal vesicle were prepared as one left and one right longitudinal section, with the vertical axis as the cut surface. These sections were embedded in paraf®n, stained with hematoxylin and eosin, and subjected to histologic examination. The treatment groups were compared with regard to the incidence of carcinomas and atypical hyperplasias occurred in the ventral lobe of the prostate. Other portions of the prostate did not produce any cancer lesion and the incidences of atypical hyperplasia were compared between each treatment group. Histologic examination was performed under the supervision of one of the authors (TS).
As statistical analyses, the data for the ®nal body weights, accessory sex organ weights, and incidence of carcinomas and atypical hyperplasias were compared by analysis of variance (ANOVA, Fisher's PSLD, Stat View). Table 1 presents the mean ®nal body weight of the rats in each treatment group and a comparison of the weights of each portion of the accessory sex organs as a percentage of the body weight. In total body weight, there were no signi®cant differences between each group except the groups administered YM116. The weights of accessory sex organs were signi®cantly suppressed in the experimental groups medicated, especially in the groups administered casodex. Table 2 summarizes the incidence of prostate carcinomas and atypical hyperplasias. All carcinomas were microscopic adenocarcinoma and developed only in the ventral lobe, and any visible nodule was not observed in the whole specimens. In group 1, which was administered only DMAB, 9.5% of rats developed microscopic prostate cancer. We de®ned this group as positive control. In group 2 ± 5, the incidence of neoplastic lesions was increased, and in groups 3 ± 5, the difference was statistically signi®cant (P`0.05, P`0.01 and P`0.001, respectively). In groups 6 and 7, which were administered DMAB plus YM116, there was no signi®cant differences in the incidence of adenocarcinoma compared with the control group.
Results
In contrast to the cancer lesions observed in the ventral lobe, the incidence of atypical hyperplasia in each group was variously observed. A higher incidence of atypical hyperplasia in the ventral prostate was observed in every group. In groups 2 ± 3, DMAB plus epristeride, the incidence of atypical hyperplasia in the anterior lobe was signi®cantly increased (P`0.05). On the other hand, in groups 4 ± 5, DMAB plus casodex, demonstrating the promotion effect of the microscopic cancer in the ventral lobe, the incidence of atypical hyperplasia in the anterior lobe and seminal vesicle was signi®cantly suppressed (P`0.05 and P`0.01, respectively). In group 7, DMAB plus YM116 in a dosage of 30 mg/kg, the incidence of atypical hyperplasia in the seminal vesicle was signi®-cantly inhibited (P`0.01). Table 3 shows the average serum testosterone and LH levels at autopsy. In group 3, DMAB plus epristeride in 
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the dose of 50 mg/kg, serum testosterone level was signi®cantly higher than in the control (P`0.05). In group 5, DMAB plus casodex in a dosage of 30 mg/kg, the serum testosterone level was also higher, but the difference was not statistically signi®cant. In contrast, in groups 6 ± 7, administered DMAB plus YM116, the serum testosterone level was strongly suppressed to the below-castration level. These differences were statistically signi®cant (P`0.05). Serum LH levels were comparatively stable, except in group 7, DMAB plus YM116 in the dose of 30 mg/kg.
Discussion
In our earlier studies we showed that adenocarcinomas of rat dorso-lateral and anterior prostates, and seminal vesicles were generated by administration of DMAB in combination with high doses of exogenous testosterone, and progression from microscopic cancer to macroscopic cancer was signi®cantly inhibited by 5a-reductase inhibitor (®nasteride) or pure antiandrogen (casodex). In the present study, we studied whether microscopic adenocarcinoma of the ventral lobe induced by DMAB administration under endogenous testosterone could be prevented chemically or not. Shirai et al pointed out the existence of androgen dependency in ventral lobe prostate carcinoma of rats, and these carcinoma lesions disappeared with orchidectomy. 10 We compared the relative weights of the various portions of the accessory sex organs at the end of the study. When epristeride, casodex or YM116 were administered, the weights of any portion of the accessory sex organs were signi®cantly decreased compared with those of the control group. Therefore, the dosages of these drugs in this study seemed to be signi®cant within the therapeutic dose.
With regard to the pathological ®ndings of the prevention effect, the initial prediction was completely contradicted. The signi®cant promotion effect on microscopic ventral prostate carcinoma was recognized in the casodex-medicated groups and an increasing tendency was observed in the groups medicated with epristeride. It also seemed that those effects were dose dependent in both groups. All these carcinoma lesions were microscopic adenocarcinoma and the possibility of their evolution to macroscopic cancer was not clear. However, under the endogenous testosterone environment, long-term antiandrogen medication might accelerate the potential for carcinogenesis at least in the ventral lobe of the prostate. Pure anti-androgens and 5a-reductase inhibitors are known to increase serum testosterone level and this was observed also in our experiment. Such a phenomenon was recognized dose-dependently in groups medicated with epristeride or casodex. There are some possible explanations that the increased testosterone played an enhancing role on microscopic carcinogenesis in the rat ventral prostate Ð estrogenic effects which were converted from elevated testosterone by aromatase, a testosterone effect on androgen receptors in the ventral lobe, and changes of the milieu of various growth factors. Those explanations seem to be reasonable enough because the groups having undergone YM116, in which serum testosterone markedly decreased, did not show the increment of adenocarcinoma. On the other hand, atypical hyperplasia of about 80% was observed in the control group in our experiment. We found no statistically signi®cant differences in the incidence of atypical hyperplasia among any of the treatment groups. Although there is still no proof that atypical hyperplasia lesions are actually pre-cancerous lesions in rats, evaluating these lesions might be helpful in surmising the mechanism of prevention of rat prostate carcinogenesis in the earlier phases.
YM116, C17-20 lyase inhibitor, is a novel drug which decreases the production of androgenic hormones in both the testes and adrenal glands. 13 By the continuous medication of this drug, theoretically, the testosterone value in blood can be decreased down to the measurement limit or less. In our experiment, the serum testosterone levels of this group signi®cantly decreased compared with those of the control group. However, a cancer inhibitor effect was not clearly recognized with group medicated with YM116. However, the incidence of atypical hyperplasia decreased in the anterior lobe and seminal vesicles in this group compared with those of control group and groups administered other drugs. It is known that, clinically, human prostate shows an increase in the incidence of latent cancer with the aging process. In addition, the incidence of latent prostate cancer shows little variation as a function of geographic or racial differences. 14 According to our current study, it seems that long-term antiandrogen therapy, which raise the serum testosterone value as a result, might promote the incidence of microscopic ventral prostate cancer of rats. It is necessary to study whether long-term administration of an antiandrogenic agent would promote the genesis of latent cancer.
Our results were contradictory to the results of our previous studies; 6,7 exogenous high-dose testosterone in combination with DMAB completely inhibited carcinogenesis in the ventral lobe, whereas it signi®cantly promoted carcinogenesis in the other portions of the accessory sex organs. It has been generally acknowledged that elevated androgen levels may be critically involved in the genesis of prostate cancer. However, an argument contrary to this prevalent opinion exists; that is declining rather than high levels of androgens probably contribute more to human prostate carcinogenesis, and androgen supplementation would probably lower the incidence of the disease. 15 The contradictions observed in our experiments may give us a tool to solve the above argument and to study the complicated actions of androgen in the carcinogenesis of the prostate. 
